Exosome isolation manufacturing and characterization
New service to reliably and reproducibly isolate exosomes from almost any biofluid.
Amsbi has announced an exosome isolation, manufacturing and characterization service to enable R&D groups to accelerate their discovery and development activities.
Exosomes are small membrane vesicles with a size ranging from 40 to 100 nm. They are known to serve as functional mediators in cell interaction leading to cancer metastasis and have also been implicated in neurodegenerative diseases. Metastasis is a complex multistep process of cancer cell invasion, survival in blood vessels, attachment to and colonization of the host organ. Exosomes influence every step of this cascade and therefore represent a novel strategy for cancer therapy.
Drawing upon many years’ experience of working with exosomes, Amsbio is able to reliably and reproducibly isolate exosomes from almost any biofluid including plasma and tissue culture media, cerebrospinal fluid, synovial fluid, and even challenging fluids such as mouse bronchial alveolar fluid.
The new service enables labs to simply provide Amsbio with a biofluid and in return receive high-quality, functional exosomes that are ready to use. Backed by expert scientific support, the Amsbio exosome isolation and manufacturing service is available across a range of production scales to suit research needs now and development needs in future.
All exosomes supplied by Amsbio come complete with Nanoparticle Tracking Analysis (NTA) characterization data. NTA characterization data provides a clearer picture of the quality of your exosomes without needing to invest in your own NTA instrument. A typical NTA report includes particle analysis data on your exosome including the mean and mode diameter size, particle concentration, and video of the collected data, all gathered in triplicate. This service can also be offered on exosome samples prepared in your own lab.
Related News
-
News Swiss pharma industry warns US tariffs could harm global patient care
The Swiss pharmaceutical sector has raised alarms over new US tariffs on medicines, warning of disrupted supply chains, increased costs, and delayed innovation, all of which could jeopardise patient access to essential treatments worldwide.
-
News Women in Pharma: CPHI India – India’s Pharmaceutical Industry and Gender Inclusion Challenges
India’s pharmaceutical industry has emerged as a significant player in the global market, valued at USD 50 billion in FY 2023-2024, according to Frost & Sullivan’s analysis. This sector encompasses a diverse portfolio, including drugs, vacc... -
News Biogen acquires Apellis Pharmaceuticals to boost immunology and rare disease profile
Biogen Inc. has announced its acquisition of Apellis Pharmaceuticals, Inc., a move that is set to significantly enhance its growth portfolio in immunology and rare diseases. The agreement, valued at approximately US$5.6 billion, will see Biogen purchas... -
News Gilead Sciences acquires Ouro Medicines for over US$2 billion
Gilead Sciences confirms a deal to take over Ouro Medicines, adding to a portfolio of therapies for autoimmune diseases.
-
News Women in Pharma: Advancing Women's Health
Discover the latest innovations in technologies and therapeutics that are revolutionising women's health in our latest CPHI Online Women in Pharma infographic.
-
News CPHI Pharma Awards 2026: Recognising Excellence in an Evolving Industry
Submissions now open — deadline May 16
-
News Dr Reddy's to launch generic semaglutide in India
Dr Reddy’s Laboratories, one of India’s leading pharmaceutical companies, is preparing to launch a generic version of semaglutide, branded as Obeda, in March. Obeda is expected to provide a more affordable alternative to Ozempic a... -
News Frontier Biotech and GSK Forge RNA Therapy Partnership
Frontier Biotechnologies and GSK have entered a global licensing agreement to advance small interfering RNA (siRNA) therapeutics. This collaboration grants GSK exclusive rights to develop and commercialise two promising siRNA candidates, marking a mile...